Modified-release products Enteric coatings

Intravenous administration, or the use of enteric-coated formulations or modified-release products all appear to reduce the risk both of bleeding and more particularly of erosions/ulceration. However, because of the indirect effect noted above, such formulations do not eliminate the risk, although they may reduce the incidence of... 

The pharmaceutical and biological availability of eight commercial furose-mide preparations was compared including two products with modified release properties [67], an enteric-coated tablet and a sustained-release preparation, in the form of a capsule containing diffusion pellets [28], A correlation between the rate of dissolution of different techniques and the area under the plasma concentration time curve was documented. The sustained-release preparation and the enteric-coated formulation clearly showed different pharmacokinetic behavior compared with conventional tablets. Although the literature mentions the maximal absorption at pH 5.5, the modified release formulations only showed a relative bioavailability of 80%. 

---